期刊文献+

短棒状杆菌外用制剂安全性的评价

Evaluation in safety for external application of Corynebactrium parvum preparation
下载PDF
导出
摘要 研究短棒状杆菌外用剂型,为体外用药开辟新途径。将短棒状杆菌接种在适宜培养基上,连续扩增传代,培养终液稀释成不同浓度。依照新药管理办法,在动物体内进行各种安全性试验。结果显示:经急性毒性试验、长期毒性试验、生殖毒性试验,皮肤光敏试验、局部刺激试验等测定,在动物体内未见到毒性反应。该试验为短棒状杆菌外用制剂的开发提供了安全性依据。 To develop the Corynebactrium parvum preparation on external application and investigate related advanced development. Corynebactrium parvum was inoculated in a proper culture medium and passaged in succession. Safety tests were performed in mice and rabbit by using diluted culture fluid according to requirements in relation to development of the new medicine. The results showed that the tests did not bave toxic effect on endurance limit,long toxigenicity, reproductive function,ray radiation injury and local stimulation. It provided a safe basis for external application of Corynebactrium parvum preparation.
出处 《微生物学免疫学进展》 2006年第4期23-26,共4页 Progress In Microbiology and Immunology
关键词 短棒状杆菌 外用给药 安全性 Corynebactrium parvum External application Safety
  • 相关文献

参考文献6

二级参考文献7

  • 1中华人民共和国药政局.新药(西药)临床前研究指导原则(药学、药理学、毒理学)[M].北京,1993.198-201.
  • 2中华人民共和国卫生部药政局,新药(西药)临床前研究指导原则(药学药理学毒理学),1993年,198页
  • 3Adlam C,Scott MT. Lymphoreticular stimulatory properties of Corynebaterium parvum and related bacteria. J Med Microbiol,1973,6:261-265.
  • 4Sliiivic VS,Warson SR.The adjuvant effect of C.parvum:T-cell dependence of macrophage activation. J Exp Med, 1977,145:45-57.
  • 5Lipton A, Harvey HA, Balch CM, et al. Corvnebacterium parvum versus Bacille Calmette-Guerin adjvant immunotherapy of Stage Ⅱ malignant melanoma. J Clin Oncol, 1991,9:1151-1156.
  • 6Anrell JL, Wheat RW. Antitunor activity and lymuhoreticular stimulation properties of fractions isolated from Gorynebacterium parvum. Cancer Res, 1979,9: 3554-3555.
  • 7张岫美,魏欣冰,盛少虎,贾伟,侯宗良,李建淮.核酸口服液的药理研究[J].中国生化药物杂志,1998,19(3):121-123. 被引量:4

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部